Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2016 Apr:164:29-36.
doi: 10.1016/j.ajo.2015.12.028. Epub 2015 Dec 31.

Dissociations of the Fluocinolone Acetonide Implant: The Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study

Janet T Holbrook  1 , Elizabeth A Sugar  2 , Alyce E Burke  1 , Albert T Vitale  3 , Jennifer E Thorne  4 , Janet L Davis  5 , Douglas A Jabs  6 ; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group
Collaborators, Affiliations
Randomized Controlled Trial

Dissociations of the Fluocinolone Acetonide Implant: The Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study

Janet T Holbrook et al. Am J Ophthalmol. 2016 Apr.

Abstract

Purpose: To describe fluocinolone acetonide implant dissociations in the Multicenter Uveitis Steroid Treatment (MUST) Trial.

Design: Randomized clinical trial with extended follow-up.

Methods: Review of data collected on the first implant in the eye(s) of participants. Dissociation was defined as the drug pellet no longer being affixed to the strut and categorized as spontaneous or surgically related.

Results: A total of 250 eyes (146 patients) had at least 1 implant placed. Median follow-up time after implant placement was 6 years (range 0.5-9.2 years). Thirty-four dissociations were reported in 30 participants. There were 22 spontaneous events in 22 participants; 6-year cumulative risk of a spontaneous dissociation was 4.8% (95% confidence interval [CI]: 2.4%-9.1%). The earliest event occurred 4.8 years after placement. Nine of 22 eyes with data had a decline in visual acuity ≥5 letters temporally related to the dissociation. Thirty-nine implant removal surgeries were performed, 33 with replacement. Twelve dissociations were noted during implant removal surgeries in 10 participants (26%, 95% CI 15%-48%); 5 of these eyes had a decline in visual acuity ≥5 letters after surgery. The time from implant placement to removal surgery was longer for the surgeries at which dissociated implants were identified than for those without one (5.7 vs 3.7 years, P < .001). Overall, visual acuity declined 15 or more letters from pre-implant values in 22% of affected eyes; declines were frequently associated with complications of uveitis or its treatment.

Conclusion: There is an increasing risk of dissociation of Retisert implants during follow-up; the risk is greater with removal/exchange surgeries, but the risk of both spontaneous and surgically related events increases with longevity of the implants. In 22% of affected eyes visual acuity declined by 15 letters. In the context of eyes with moderate to severe uveitis for years, this rate is not unexpected.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: Dr. Holbrook (none); Dr. Sugar (none); Ms. Burke (none); Dr. Vitale (Aclont, consultant); Dr. Thorne (AbbVie and Xoma, medical advisory boards; Gilead, consultant; Allergan, Inc., grant support); Dr. Davis (none); and Dr. Jabs (Applied Genetic Technologies, Data and Safety Monitoring Committee; Santen, Inc., consultant).

Figures

Figure 1
Figure 1
Fluocinolone acetonide implant placements and dissociations in the MUST Trial and Follow-up Study (December 2005 to March 2015)
Figure 2
Figure 2
Kaplan Meier curve of time to spontaneous dissociations of fluocinolone acetonide implants in the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.
See this image and copyright information in PMC

References

    1. Drugs @ FDA, FDA Approved Drug Products. [Accessed 16 September 2014]; http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseacti....
    1. Mahammed DA, Sweet BV, Elner SG. Retisert: is the new advance in treatment of uveitis a good one. Ann Pharmacother. 2007;41(3):449–455. - PubMed
    1. Itty S, Callanan D, Jones R, Pecen P, Martel J, Jaffe G. Spontaneous dislocation of fluocinolone acetonide impland pellets from their suture struts. Am J Ophthalmol. 2015;159(5):868–876. - PubMed
    1. Callanan DG, Jaffe GJ, Martin DM, Pearson PA, Comstock Tl. Treatment of posterior uveitis with a fluocinolone acetonide implant. Arch Ophthalmol. 2008;126(9):1191–1201. - PubMed
    1. Akduman L, Cetin En, Levy J, Brecker MD, Mackensen F, Lim L. Spontaneous dissociation of Retisert pellet. Ocular Immunol Inflam. 2013;21(1):87–89. - PubMed

Publication types

MeSH terms